Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Por um escritor misterioso

Last updated 24 setembro 2024

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Cancers, Free Full-Text

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature - Yolanda Piña, Brittany R. Evernden, Nikhil Khushalani, Kim Margolin, Hussein

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - The Lancet Oncology

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Full article: Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma

Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids - ScienceDirect

Nivolumab and Relatlimab for Advanced Melanoma - NCI

The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis

Ipilimumab (Yervoy) Drug Information

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Cureus, Aggressive Stereotactic Radiosurgery Coupled With Immune and Targeted Therapy for Recurrent Melanoma Brain Metastases: A Case Report and Literature Review

Recomendado para você